Ziccum AB (publ) is sponsoring one of the most well-attended international events in the field of mRNA-based therapeutics in Boston MA, July 26-28. Ziccum CEO Ann Gidner will present the company’s unique drying technology for biopharmaceuticals. Furthermore, the company will exhibit a Poster on its current in-house mRNA project, successfully drying active mRNA materials into a thermostable bioactive dry powder.
mRNA-based therapeutics and vaccines is one of the fastest-growing fields within biopharmaceutics, with over 800 mRNA drug projects currently in development. A central event in the scientific and business calendar for mRNA professionals is the Global mRNA-Based Therapeutics Summit. The 3rd summit will take place July 26-28 in Boston MA.
Ziccum CEO Ann Gidner will present on Day 1 of the event, Thursday July 27. Her Presentation is titled A Novel Unit Operation Successfully Drying mRNA/LNP by Mass Transfer. It will cover the technology principle allowing for ambient drying, its valuable thermostability effects and the implementation for industrial use.
Ziccum will also take part in the Poster Exhibition at the event, outlining aspects from the latest stage of its milestone in-house mRNA project. On March 20, 2023, the company announced that it had successfully nebulized and dried active mRNA materials, plus demonstrated a commercially viable level of mRNA activity.
CEO Ann Gidner: “The Summit is a landmark event for the international business and scientific mRNA community – and we believe that our unique capabilities within mRNA make our technology a key topic here. We look forward to sponsoring, networking and presenting at the event.”